Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses three classes of thiazole-bearing compounds in drug development and presents preclinical findings but reports no new experimental results, highlighting the need for further drug discovery.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

This study introduces a novel visible light-mediated intramolecular [2+2] cycloaddition process that forms 6-azabicyclo[3.1.1]heptanes, offering a new synthesis route for bioisosteric mimetics used in drug discovery, potentially expanding medicinal chemistry applications beyond traditional limitations.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This study presents a Cu-catalyzed atroposelective method achieving high stereoselectivity for synthesizing chiral biaryl N-oxides, with product 3e showing promising therapeutic efficacy against triple-negative breast cancer in cell lines MDA-MB-231 and MDA-MB-468.

In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.

This study proposes that combining trazodone and clomiphene citrate could potentially restore libido synaptic circuits and treat post-finasteride syndrome, which involves persistent sexual dysfunction after discontinuing finasteride treatment.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This study examined 16 sporadic trichoblastic tumors and found that although one showed malignant transformation, clinical follow-up revealed no residual or metastatic disease. RNA sequencing indicated a high tumor mutational burden and absence of a UV-related signature, helping to distinguish these tumors from similar growths.

In this study, researchers successfully synthesized a rigid 3a-arylhexahydropentalene-1,6-dione from the easily accessible starting material cyclopent-2-en-1-one, highlighting a structural motif common in natural products and pharmaceuticals.

This study isolated highly pure oleanolic and maslinic acids from olive milling residues, exploring their chemical reactions, including the formation of finasteride precursors.

This review discusses the potential of using triads of repositioned medicines targeting multiple pathogenic mechanisms to prevent or delay retina degeneration, but reports no new results.

This study found that ethanolic, aqueous, and hydroethanolic extracts of Tridax procumbens inhibited mitosis and caused mutagenic effects on cell division in Allium cepa root meristematic cells.

This invention reports piperazine derivatives as potent inhibitors of type 3 17β-hydroxysteroid dehydrogenase, suggesting potential therapeutic applications in treating prostate cancer, acne, and androgenic alopecia.

This study discusses trichodynia, a painful scalp condition often linked to various forms of alopecia and psychiatric comorbidities, highlighting its clinical diagnosis, lack of specific treatments, and suggesting the need for more research to explore effective therapies.

This study outlines trichodynia, a painful scalp condition often linked with various types of alopecia and psychiatric disorders, noting the absence of specific treatments and highlighting the need for further research on therapeutic options.

This article reviews two cases of monilethrix in siblings, detailing their clinical and dermatoscopic characteristics, but reports no new findings.

This case report describes a 2-year-old boy diagnosed with trichothiodystrophy, characterized by fragile hair, intellectual damage, diminished fertility, and short stature.

This study evaluated the phytochemical properties and in-vitro anti-fungal activity of Tridax procumbens but reports no new clinical results.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.

This study found that tribuloside, a flavonoid from Tribulus terrestris L., enhances melanin production in human melanocytes, zebrafish, and human skin samples without causing toxicity, potentially through inhibiting PDE to increase cAMP levels and promote the melanin biosynthesis pathway.

This integrative review found that triamcinolone hexacetonide remains the primary treatment for mild to moderate alopecia areata but noted its significant side effects with prolonged use, while emerging therapies like PRP and minoxidil offer promising alternative benefits with fewer risks.